Peptide Therapeutics Reference
Peptide drugs are approved and regulated as individual products, not as a single class — so there is no official master list of "approved peptides." What the primary literature does document, agency by agency and product by product, is narrower and checkable. The table below collects the approval facts our peptide-drugs coverage has verified against primary sources; the ten sections beneath it index everything else this reference covers, from GLP-1 pharmacology to laboratory assay methods.
What the record actually shows
| Approval fact | Class / agent | Figure | Window | Source |
|---|---|---|---|---|
| Peptide-drug conjugates approved for cancer | PDC | 2 products | as of 2024 | PMID 38194773 |
| New type 2 diabetes drug classes approved on glycemic control | GLP-1 receptor agonists (1 of 3 classes) | 3 classes | 15 yrs to 2018 | PMID 30294953 |
| Oncology biosimilars approved, FDA | biosimilar | 16 applications | 2007–2020 | PMID 33271114 |
| Oncology biosimilars approved, EMA | biosimilar | 33 applications | 2007–2020 | PMID 33271114 |
This is not an approved-peptide roster — see why no such list exists for the full counting-rule breakdown. It is the set of approval facts we can currently trace to a primary source.
Sections in this reference
-
Peptide Drugs: Pharmacology, FDA-Approved Agents, and Clinical Applications (coming soon)
FDA and EMA regulatory pathways, approval counts, and how peptide drugs are classified against small-molecule therapeutics.
-
GLP-1 Receptor Agonists: Pharmacology, Comparative Efficacy, and Clinical Evidence (coming soon)
GLP-1 receptor agonist pharmacology, comparative trial data, and mechanism across the approved and investigational agents.
-
Peptide Hormones: Structure, Receptor Signaling, and Clinical Pharmacology (coming soon)
Endogenous peptide hormones and their synthetic analogs — receptor signaling, structure, and clinical pharmacology.
-
Solid-Phase Peptide Synthesis: Fmoc Strategy, Purification, and Characterization (coming soon)
Solid-phase peptide synthesis chemistry, purification methods, and manufacturing considerations from bench to scale.
-
What Are Peptides? Amino Acids, Peptide Bonds, and Biological Function Explained (coming soon)
Foundational peptide biology and chemistry — structure, bonding, and how peptides differ from proteins and small molecules.
-
GHRH Analogs: Pharmacology of Tesamorelin, Sermorelin, and GHS-R1a Agonists (coming soon)
Growth hormone releasing hormone analogs — tesamorelin, sermorelin, and GHS-R1a agonist pharmacology and clinical evidence.
-
Melanocortin Peptides: MC1R/MC4R Agonists, Afamelanotide, and Bremelanotide Pharmacology (coming soon)
Melanocortin receptor agonists — MC1R/MC4R pharmacology, afamelanotide, and bremelanotide clinical data.
-
Peptide Analysis: HPLC, Mass Spectrometry, and COA Interpretation (coming soon)
Peptide analysis methods — HPLC, mass spectrometry, amino acid analysis, and how to interpret a certificate of analysis.
-
Peptide Pharmacokinetics: Half-Life, Clearance, Lipidation, and Depot Formulations (coming soon)
Peptide half-life, clearance, and the lipidation, PEGylation, and depot strategies used to extend duration of action.
-
Peptide Research Methods: Receptor Binding Assays, Cell-Based Models, and Laboratory Practice (coming soon)
Peptide research methodology — receptor binding assays, cell-based and in vivo models, and laboratory reconstitution practice.